Graham Capital Management, L.P. Neurocrine Biosciences Inc Transaction History
Graham Capital Management, L.P.
- $4.42 Billion
- Q3 2024
A detailed history of Graham Capital Management, L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Graham Capital Management, L.P. holds 24,839 shares of NBIX stock, worth $3.65 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
24,839Holding current value
$3.65 Million% of portfolio
0.06%Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
631Shares Held
93.9MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$2.08 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.47 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$756 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$378 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$274 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $14B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...